Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Conditions: HIV Infections; Tuberculosis; Candidiasis, Esophageal; Cryptococcosis; Leishmaniasis; Toxoplasmosis Intervention: Other: CD4 cell count Sponsor: Singh, Ranjan Kumar, M.D. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 20, 2019 Category: Research Source Type: clinical trials
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.
Condition: Latent Tuberculosis Interventions: Drug: Rifampin double dose; Drug: Rifampin triple dose; Drug: Rifampin standard dose Sponsors: McGill University; Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2019 Category: Research Source Type: clinical trials
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
Condition: Latent Tuberculosis Interventions: Drug: Rifampin double dose; Drug: Rifampin triple dose; Drug: Rifampin standard dose Sponsors: McGill University; Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2019 Category: Research Source Type: clinical trials
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.
Condition: Latent Tuberculosis Interventions: Drug: Rifampin double dose; Drug: Rifampin triple dose; Drug: Rifampin standard dose Sponsors: McGill University; Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2019 Category: Research Source Type: clinical trials
Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy
Condition: Tuberculosis Intervention: Drug: Rifampin 300 Mg Oral Capsule Sponsor: Makerere University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials
FDA Advisory Committee Votes Favorably on the Question of the Effectiveness and Safety of Pretomanid in Combination with Bedaquiline and Linezolid for Treatment of Highly Drug-Resistant Forms of Tuberculosis
NEW YORK (June 6, 2019)—TB Alliance announced today that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted (14 yes, 4 no, 0 abstain) that there is substantial evidence of the effectiveness and sufficient... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 6, 2019 Category: Pharmaceuticals Source Type: clinical trials
Assessing the Ability of the T-SPOT ®.TB Test (IQ)
Condition: Tuberculosis Intervention: Sponsor: Oxford Immunotec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 4, 2019 Category: Research Source Type: clinical trials
